8-KItem 5.02 · Officer/Director ChangeItem 9.01 · Financial Statements
J&J names Tom Cavanaugh to lead Innovative Medicine as Jennifer Taubert retires
Filed with the SEC on · Summarized by InvestorsBot
Jennifer Taubert will retire as Johnson & Johnson’s Executive Vice President and Worldwide Chairman of Innovative Medicine on September 1, 2026, after more than 21 years with the company. Tom Cavanaugh, currently Company Group Chairman for North America, Innovative Medicine, will succeed her and join J&J’s Executive Committee; the business generated more than $60 billion in annual revenue under Taubert’s leadership.